Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170231 | 0.94 | — | — | |
| SCHEMBL45523 | 0.94 | — | — | |
| SCHEMBL6380221 | 0.92 | ALDH1A1 (0.42) | ALDH1A1THRBRECQLCYP2C19MAPT | |
| Iodide SCHEMBL1478059 | 0.89 | ALDH1A1 (0.40) | ALDH1A1THRBRECQLCYP2C19MAPT | |
| Acetonitrile SCHEMBL28207157 | 0.82 | ALDH1A1 (0.35) | ALDH1A1THRBRECQLCYP2C19MAPT | |
| SCHEMBL11290734 | 0.77 | ALDH1A1 (0.44) | ALDH1A1THRBRECQLCYP2C19MAPT | |
| SCHEMBL11335436 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL11288648 | 0.74 | ALDH1A1 (0.42) | ALDH1A1THRBRECQLCYP2C19MAPT | |
| Hydrochloric Acid SCHEMBL11288423 | 0.74 | ALDH1A1 (0.42) | ALDH1A1THRBRECQLCYP2C19MAPT | |
| SCHEMBL8872262 | 0.73 | CYP3A4 (0.34) | ALDH1A1THRBRECQLCYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2482857-A1 | HYDROXYLATED CONTRAST ENHANCEMENT AGENTS AND INTERMEDIATES THEREOF | General Electric Company (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039244-A1 | HYDROXYLATED CONTRAST ENHANCEMENT AGENTS AND INTERMEDIATES THEREOF | GENERAL ELECTRIC COMPANY (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077396-A1 | INTERMEDIATES FOR HYDROXYLATED CONTRAST ENHANCEMENT AGENTS | GENERAL ELECTRIC COMPANY (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077396-A1 | INTERMEDIATES FOR HYDROXYLATED CONTRAST ENHANCEMENT AGENTS | C1R, HCAR3, C3AR1 | ALDH1A1 4130/4885THRB 2413/4885RECQL 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.